Oncolys BioPharma Inc.
4588.T
Price:
$923
Market Cap:
$22.93B
Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pr...[Read more]
Industry
Biotechnology
IPO Date
2013-12-06
Stock Exchange
JPX
Ticker
4588.T
PE Ratio
[-9.92]
ROE
[-110.85%]
Current Ratio
[6.78]
Dividend Yield
[0%]
Enterprise Value
[21.91B]
Dividend History
The PE Ratio as of December 2025 (TTM) for Oncolys BioPharma Inc. (4588.T) is -9.92
According to Oncolys BioPharma Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -9.92. This represents a change of 51.51% compared to the average of -6.55 of the last 4 quarters.
Oncolys BioPharma Inc. (4588.T) Historical PE Ratio (quarterly & annually)
How has 4588.T PE Ratio performed in the past?
The mean historical PE Ratio of Oncolys BioPharma Inc. over the last ten years is -9.99. The current -9.92 PE Ratio has changed 9.83% with respect to the historical average. Over the past ten years (40 quarters), 4588.T's PE Ratio was at its highest in in the June 2019 quarter at 79.58. The PE Ratio was at its lowest in in the June 2020 quarter at -29.93.
Average
-9.99
Median
-7.65
Minimum
-29.33
Maximum
-5.21
Oncolys BioPharma Inc. (4588.T) PE Ratio by Quarter and Year
Discovering the peaks and valleys of Oncolys BioPharma Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 196.60%
Maximum Annual PE Ratio = -5.21
Minimum Annual Increase = -64.80%
Minimum Annual PE Ratio = -29.33
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -6.71 | 28.94% |
| 2023 | -5.21 | -34.50% |
| 2022 | -7.95 | 43.76% |
| 2021 | -5.53 | -46.45% |
| 2020 | -10.32 | -64.80% |
| 2019 | -29.33 | 196.60% |
| 2018 | -9.89 | 34.53% |
| 2017 | -7.35 | -31.06% |
| 2016 | -10.66 | 54.59% |
| 2015 | -6.90 | -28.57% |
Oncolys BioPharma Inc. (4588.T) Average PE Ratio
How has 4588.T PE Ratio performed in the past?
The current PE Ratio of Oncolys BioPharma Inc. (4588.T) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-6.62
5-year avg
-7.14
10-year avg
-9.99
Oncolys BioPharma Inc. (4588.T) PE Ratio vs. Peers
How is 4588.T’s PE Ratio compared to its peers?
Oncolys BioPharma Inc.’s PE Ratio is less than StemRIM (-8.18), greater than CanBas Co., Ltd. (-13.23), greater than Japan Tissue Engineering Co., Ltd. (-71.06), less than Astena Holdings Co., Ltd. (-9.47), less than CellSeed Inc. (-9.03), less than Fuso Pharmaceutical Industries,Ltd. (7.01), greater than ReproCELL Incorporated (-117.95), greater than RaQualia Pharma Inc. (-49.21), less than MediciNova, Inc. (-6.48), less than Ohki Healthcare Holdings Co.,Ltd. (6.84),
| Company | PE Ratio | Market cap |
|---|---|---|
| -8.18 | $15.78B | |
| -13.23 | $15.57B | |
| -71.06 | $20.39B | |
| -9.47 | $18.41B | |
| -9.03 | $9.36B | |
| 7.01 | $18.29B | |
| -117.95 | $14.87B | |
| -49.21 | $27.61B | |
| -6.48 | $11.53B | |
| 6.84 | $19.38B |
Build a custom stock screener for Oncolys BioPharma Inc. (4588.T) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncolys BioPharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Oncolys BioPharma Inc. (4588.T) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Oncolys BioPharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is Oncolys BioPharma Inc.'s PE Ratio?
How is the PE Ratio calculated for Oncolys BioPharma Inc. (4588.T)?
What is the highest PE Ratio for Oncolys BioPharma Inc. (4588.T)?
What is the 3-year average PE Ratio for Oncolys BioPharma Inc. (4588.T)?
What is the 5-year average PE Ratio for Oncolys BioPharma Inc. (4588.T)?
How does the current PE Ratio for Oncolys BioPharma Inc. (4588.T) compare to its historical average?